Type 2 Diabetes
Conditions
Brief summary
Reduction of postprandial hyperglycemia (PPHG) is a major target in the treatment of type 2 diabetes (T2D). Skipping breakfast has been consistently associated with higher HbA1c and overall PPHG in subjects with type 2 diabetes (T2D). Our aim was to explore the effect of skipping vs eating breakfast on PPHG after subsequent isocaloric (700kcal) lunch and dinner
Detailed description
In type 2 diabetic individuals the omission of breakfast is associated with significant increase in HbA1C and all-day postprandial hyperglycemia even without overeating in the evening. In contrast, high-energy breakfast and low-energy dinner result in a significant reduction of all-day postprandial glycaemia Similarly, 3 months of high-energy breakfast led to a 5% reduction in HbA1C levels in type 2 diabetes participants Despite the growing evidence showing the beneficial effects of breakfast consumption on overall postprandial hyperglycemia and HbA1C levels, very little is known regarding the relationship between breakfast skipping and all-day glycemic excursions in type 2 diabetes patients. Therefore, to test whether breakfast skipping influences metabolic responses to the following meals in type 2 diabetes patients during the same day, we explored the postprandial glycemic response to identical lunch and dinner meal tests with or without breakfast.
Interventions
OTHERBreakfast eating (YesB)
On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
OTHERBreakfast skipping (NoB)
On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
Sponsors
Tel Aviv University
Hospital de Clinicas Caracas
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* BMI: 26-34 kg/m2. * HbA1c \> 7 % * T2D since \< 10 yrs, * . Only non treated or treated with oral antidiabetic drugs * Those treated with insulin or GLP-1 analogs will be excluded.
Exclusion criteria
* Type 1 diabetes * Serum creatinine level \> 1.5 mg/dl * Pulmonary disease, psychiatric, immunological, neoplastic diseases or severe diabetic complications,such as cardiovascular disease, cerebrovascular disease, proliferative diabetic retinopathy, gastroparesis or anemia (Hg \> 10g/dL) or underwent bariatric surgery. * Abnormal liver function tests * Participating in dietary program or using of weight-loss medications * History (within one year) of illicit drug abuse or alcoholism. * Use of psychotropic or anoretic medication during the month immediately prior to study onset
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postprandial Glucose | 6 weeks | Postprandial Glucose will be measure after lunch and dinner |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postprandial Free Fatty Acids | 6 weeks | Postprandial Free Fatty Acids will be measure after lunch and dinner |
| Postprandial intact GLP-1 | 6 weeks | Postprandial intact GLP-1 will be measure after lunch and dinner |
| Postprandial Insulin | 6 weeks | Postprandial Insulin will be measure after lunch and dinner |
| Postprandial Glucagon | 6 weeks | Postprandial Glucagon will be measure after lunch and dinner |
Outcome results
None listed